Search Results

By The ASCO Post Staff  / Wednesday, April 22, 2015 12:59 PM

AACR 2015: Olaparib and Investigational PI3K Inhibitor BKM120 Combination Active Against Ovarian and Breast Cancer Subtypes

Combination treatment with the poly ADP-ribose polymerase (PARP) inhibitor olaparib (Lynparza) and the investigational phosphatidylinositol-3-kinase (PI3K) inhibitor BKM120 was safe and yielded evidence of clinical benefit for women with triple-negative breast cancer and for those with high-grade...